MX2007011105A - Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. - Google Patents

Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.

Info

Publication number
MX2007011105A
MX2007011105A MX2007011105A MX2007011105A MX2007011105A MX 2007011105 A MX2007011105 A MX 2007011105A MX 2007011105 A MX2007011105 A MX 2007011105A MX 2007011105 A MX2007011105 A MX 2007011105A MX 2007011105 A MX2007011105 A MX 2007011105A
Authority
MX
Mexico
Prior art keywords
sub
alkyl
alkoxy
sup
hydroxy
Prior art date
Application number
MX2007011105A
Other languages
English (en)
Inventor
Kazunari Nakao
Yuji Shishido
Misato Hirano
Tadashi Inoue
Takeshi Hanazawa
Hirotaka Tanaka
Satoshi Nahayama
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2007011105A publication Critical patent/MX2007011105A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Esta invencion proporciona un compuesto de formula (I) (ver formula (I)): en la que R1 representa alquilo (C1-C6); R2 representa un atomo de hidrogeno, un atomo de halogeno, un grupo hidroxi, alquilo (C1-C6), alcoxi (C1-C6), hidroxi-alquilo (C1-C6), alcoxi (C1-C6)-alquilo (C1-C6) o halo-alquilo (C1-C6); R3 representa un atomo de halogeno, alquilo (C1-C6), alcoxi (C1-C6), hidroxi-alcoxi (C1-C6), alcoxi (C1-C6)-alquilo (C1-C6), alcoxi (C1-C6)-alcoxi (C1-C6), haloalquilo (C1-C6), alquil (C1-C6)-tio, alquil (C1-C6)-sulfinilo, alquil (C1-C6)-sulfonilo, [alquil (C1-C6)]NH- o [alquil (C1-C6)]2N-; R4 representa un atomo de halogeno, alquilo (C1-C6), haloalquilo (C1-C6), alcoxi (C1-C6), hidroxi-alcoxi (C1-C6), alcoxi (C1-C6)-alquilo (C1-C6), alcoxi (C1-C6)-alcoxi (C1-C6), [alquil (C1-C6)]NH- o [alquil (C1-C6)]2N-; R5 representa un atomo de halogeno, alquilo (C1-C6), alcoxi (C1-C6), hidroxi-alcoxi (C1-C6), alcoxi (C1-C6)-alquilo (C1-C6), alcoxi (C1-C6)-alcoxi (C1-C6), haloalquilo (C1-C6), alquil (C1-C6)-tio, alquil (C1-C6)-sulfinilo, alquil (C1-C6)-sulfonilo, [alquil (C1-C6)]NH-, [alquil (C1-C6)]2N- H2N-alcoxi (C1-C6), alquil (C1-C6)-NH-alcoxi (C1-C6), [alquil (C1-C6)]2N-alcoxi (C1-C6), H2N-alcoxi (C1-C6)-alquilo (C1-C6), alquil (C1-C6)-NH-alcoxi (C1-C6)-alquilo (C1-C6) o [alquil (C1-C6)]2N-alcoxi (C1-C6)-alquilo (C1-C6); y * indica un centro quiral; o una sal farmaceuticamente aceptable del mismo o un solvato del mismo; estos compuestos son utiles para el tratamiento de estados de enfermedad provocados por sobreactivacion del receptor VR1 tal como dolor o similares en mamiferos; esta invencion tambien proporciona una composicion farmaceutica que comprende el compuesto anterior.
MX2007011105A 2005-03-10 2006-02-24 Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. MX2007011105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66097805P 2005-03-10 2005-03-10
PCT/IB2006/000539 WO2006095263A1 (en) 2005-03-10 2006-02-24 Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds

Publications (1)

Publication Number Publication Date
MX2007011105A true MX2007011105A (es) 2007-10-08

Family

ID=36297248

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007011105A MX2007011105A (es) 2005-03-10 2006-02-24 Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.

Country Status (16)

Country Link
US (1) US7566739B2 (es)
EP (1) EP1858865B1 (es)
JP (1) JP4906839B2 (es)
AR (1) AR052938A1 (es)
AT (1) ATE443056T1 (es)
CA (1) CA2600409C (es)
DE (1) DE602006009231D1 (es)
DO (1) DOP2006000060A (es)
ES (1) ES2331153T3 (es)
GT (1) GT200600107A (es)
MX (1) MX2007011105A (es)
NL (1) NL1031335C2 (es)
PE (1) PE20061163A1 (es)
TW (1) TW200700398A (es)
UY (1) UY29412A1 (es)
WO (1) WO2006095263A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
EP1861357B1 (en) * 2005-03-19 2013-04-24 Amorepacific Corporation Novel compounds or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2007120012A1 (en) * 2006-04-19 2007-10-25 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
AU2007277519B2 (en) 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP2238105B1 (en) 2008-01-28 2014-04-16 Amorepacific Corporation Novel compounds as vanilloid receptor antagonists
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
JP5438103B2 (ja) 2008-07-02 2014-03-12 アモーレパシフィック コーポレイション バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物
CA2731769C (en) 2008-07-21 2013-09-10 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
KR101893751B1 (ko) 2010-07-16 2018-09-03 애브비 아일랜드 언리미티드 컴퍼니 항바이러스성 화합물의 제조 방법
BR112013001138A2 (pt) 2010-07-16 2016-07-05 Abbvie Inc ligantes de fosfina para reações catalíticas
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US20200039922A1 (en) * 2016-10-05 2020-02-06 Afecta Pharmaceuticals, Inc. High mobility group b1 protein inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810716A (en) 1986-04-11 1989-03-07 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
MX226123B (es) 1999-09-17 2005-02-07 Millennium Pharm Inc Benzamidas e inhibidores del factor xa relacionadas.
IL148698A0 (en) 1999-09-17 2002-09-12 Cor Therapeutics Inc INHIBITORS OF FACTOR Xa
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
DE60120421T2 (de) * 2000-08-21 2006-12-28 Pacific Corp. Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten
AU2001280229B2 (en) * 2000-08-21 2006-12-07 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
RU2296119C2 (ru) 2001-10-04 2007-03-27 Новартис Аг Цианоацетильные соединения, способ их получения и их применение (варианты), композиция и способ борьбы с паразитами
EP1505968A1 (en) 2002-05-13 2005-02-16 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
KR100556158B1 (ko) * 2002-10-17 2006-03-06 (주) 디지탈바이오텍 신규 엔-하이드록시 티오우레아, 우레아 및 아미드계화합물 및 이를 함유하는 약제학적 조성물
KR100707123B1 (ko) * 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물
US20050085449A1 (en) 2003-10-15 2005-04-21 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
US7417169B2 (en) 2003-10-24 2008-08-26 Kissei Pharmaceutical Co., Ltd. Amino alcohol derivatives, medicinal composition containing the same, and use of these
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物

Also Published As

Publication number Publication date
EP1858865A1 (en) 2007-11-28
NL1031335A1 (nl) 2006-09-12
CA2600409C (en) 2011-07-05
NL1031335C2 (nl) 2007-01-23
DE602006009231D1 (de) 2009-10-29
WO2006095263A8 (en) 2007-11-08
JP4906839B2 (ja) 2012-03-28
US7566739B2 (en) 2009-07-28
ATE443056T1 (de) 2009-10-15
JP2008532994A (ja) 2008-08-21
AR052938A1 (es) 2007-04-11
PE20061163A1 (es) 2006-10-27
GT200600107A (es) 2006-12-26
WO2006095263A1 (en) 2006-09-14
US20060205980A1 (en) 2006-09-14
UY29412A1 (es) 2006-10-31
EP1858865B1 (en) 2009-09-16
CA2600409A1 (en) 2006-09-14
DOP2006000060A (es) 2006-09-30
TW200700398A (en) 2007-01-01
ES2331153T3 (es) 2009-12-22

Similar Documents

Publication Publication Date Title
MX2007011105A (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
BR0313923A (pt) Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
MX2007005709A (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos.
HK1095139A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
EP2546246A3 (en) Compounds and methods for the treatment or prevention of flavivirus infections
EP2368551A3 (en) Methods of use for cyclopamine analogs
EP2426115A3 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
PL1891029T3 (pl) Związki organiczne do leczenia stanów zapalnych lub alergicznych
EP1982713A3 (en) Substituted benzoxazoles and analogues as estrogenic agents for the treatment of inflammatory bowel diseases
PL1653947T3 (pl) Pochodne oksymów (4-hydroksyfenylo)-1H-indolo-3-karbaldehydów jako środki estrogenne
WO2008076243A3 (en) Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
UA81658C2 (en) Substituted pyrimidinones
DE602004011394D1 (en) Thiazolderivate
EP2042490A3 (en) Benzimidazole derivatives as vanilloid receptor antagonists
WO2008050199A8 (en) Substituted phenylmethyl bicyclocarboxyamide compounds
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
GB0417910D0 (en) Organic compounds
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
TW200621223A (en) Acyclic 1,3-diamines and uses therefor

Legal Events

Date Code Title Description
FG Grant or registration